It has not been a good morning for MedQuist (MEDQ) . The company, which provides electronic transcription and document management services to the healthcare industry was downgraded to buy from strong buy at Credit Suisse First Boston, to market perform from top pick at Donaldson Lufkin & Jenrette, to market performer from U.S. buy list at Goldman Sachs and to neutral from buy at Merrill Lynch.
: UP to strong buy from buy at
Banc of America
: UP to strong buy from market perform at
Deutsche Banc Alex. Brown
: UP to intermediate-term accumulate at Merrill Lynch.
: UP to trading buy from market outperform at Goldman Sachs.
: UP to buy from hold at CSFB.
: DOWN to hold from buy at
: DOWN to market outperform from trading buy at Goldman Sachs.
: DOWN to hold from strong buy at
: price target DOWN to 80 from 160 at DLJ.
: DOWN to neutral from outperform at
Morgan Stanley Dean Witter
: DOWN to market perform from strong buy at DB Alex. Brown.
: DOWN to hold from strong buy at Prudential.
: DOWN to neutral from outperform at Morgan Stanley Dean Witter.
: DOWN to hold from buy at CSFB.
: NEW accumulate at Prudential.
: NEW market outperform at Goldman Sachs.
: NEW buy at CSFB; price target: 18.
: NEW buy at Lehman Brothers; price target: 44.
: NEW outperform at Lehman.
: NEW intermediate-term accumulate and long-term buy at Merrill Lynch; price target: 40.
: NEW buy at Lehman.
: NEW buy at CSFB; price target: 165; NEW market outperform at Goldman Sachs.
: NEW buy at CSFB; price target: 35.